# Single and Multiple Ascending Oral Doses of Avenanthramide

> **NCT06101784** · PHASE1,PHASE2 · COMPLETED · sponsor: **Montreal Heart Institute** · enrollment: 92 (actual)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** Avenanthramide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06101784
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-09
- **Primary completion:** 2025-06-16
- **Final completion:** 2025-06-16
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06101784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06101784, "Single and Multiple Ascending Oral Doses of Avenanthramide". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06101784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*